Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

View All Information for Patients & Visitors »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

Muscular Dystrophy

Muscular dystrophy is a rare inherited disease of the nerves and muscles that occurs mostly in males. The most common type of muscular dystrophy causes rapid muscle wasting and progressive weakness early in life, usually between the ages of 2 and 5.

Muscle wasting begins in the shoulder and pelvic areas. Fat and connective tissue may grow into muscles and cause abnormal enlargement (hypertrophy), especially in the calf muscles of the legs. Within several years muscular dystrophy affects the muscles of the upper body and arms. Eventually all the major muscles are affected.

There is no cure for muscular dystrophy. Treatment involves controlling symptoms.

Clinical Trials for Muscular Dystrophy

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

An Open Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy ATYR1940-003 Muscular Dystrophy

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients with Spinal Muscular Atrophy (SMA) Muscular Dystrophy

A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD)

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Muscular Dystrophy,

An Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early-Stage Duchenne Muscular Dystrophy (Sarepta) Muscular Dystrophy

Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD),